Research Questions:
1)To explore the differences of proteomic, metabolomic, and fMRI data in patients with MDD, AD, OCD, and SFD, and we wonder if the Integrative analysis of these data will reveal the distinct biotypes within different mental disorders.
2)The correlation between these various biotypes of omics and fMRI data with differential treatment outcomes and symptom trajectories.
3)The potential pathophysiological mechanisms across different biotypes of mental disorders.
Objectives:
1)Conduct an exploratory analysis to characterize the metabolomic and proteomic signature in MDD, AD, OCD, and SFD patients;
2)Explore the pathological changes of specific brain regions in patients with MDD, AD, OCD, and SFD patients through functional MRI;
3)Develop and validate precision classification models for MDD, AD, OCD, and SFD using multimodal data (proteomics, metabolomics, fMRI).
4)Identify biotype-specific molecular and neuroimaging signatures predictive of clinical outcomes.
Scientific Rationale: The UK Biobank’s unparalleled combination of proteomics (Olink panels), metabolomics (NMR spectroscopy), and task/resting-state fMRI enables the identification of multidimensional signatures for precision classification. Prior studies lack robust validation of such models across disorders or linkage to actionable biomarkers for personalized interventions.
Timeline:
Year 1: The examination and comparison of the metabolites and proteins in the peripheral blood samples and urine samples in MDD, AD, OCD, and SFD individuals with healthy controls, as well as the comparison between individuals with or without physical comorbidites.
Year 2: The analysis of the brain imaging data across different types of mental disorders and healthy individuals.
Year 3: The development and external validation (if feasible) of the precision classification models, as well as the manuscript preparation.